Amir Nashat


Amir Nashat is a Partner in Polaris’ Boston office. He joined Polaris in 2002 and focuses on investments in healthcare.

Amir currently represents Polaris as a Director of AgBiomeaTyr Pharmaceuticals (NASDAQ: LIFE)Fate Therapeutics (NASDAQ: FATE), Jnana Therapeutics, where he also serves as CEO, Marauder Therapeutics, Metacrine Therapeutics, Morphic Therapeutic, Olivo Labs, Promedior Pharmaceuticals, Scholar RockSelecta Biosciences (NASDAQ: SELB),  Syros Pharmaceuticals (NASDAQ: SYRS) and TARIS Biomedical.

Additionally, Amir has served as a Director of Adnexus Therapeutics (Bristol Myers Squibb), Athenix Corporation (Bayer), Avila Therapeutics (Celgene), Living Proof (Unilever), Pervasis Therapeutics (Shire Pharmaceuticals), Receptos (Celgene), and Sun Catalytix (Lockheed Martin). At Living Proof, Sun Catalytix, and Olivo Labs, Amir served as the company’s initial CEO.

Amir also serves on the Partners Innovation Fund, the Investment Advisory Committee for The Engine at MIT, and helped launch the MIT Sandbox Innovation Fund as its active president.

He previously served on the Board of the New England Venture Capital Association. He has been named to the Forbes Midas List of “Top 100 Venture Capitalists.”

Prior to joining Polaris, Amir completed his PhD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Amir also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley.